169 related articles for article (PubMed ID: 27535291)
1. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.
Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C; Leblond V
Adv Ther; 2016 Oct; 33(10):1814-1830. PubMed ID: 27535291
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Al-Sawaf O; Zhang C; Jin HY; Robrecht S; Choi Y; Balasubramanian S; Kotak A; Chang YM; Fink AM; Tausch E; Schneider C; Ritgen M; Kreuzer KA; Chyla B; Paulson JN; Pallasch CP; Frenzel LP; Peifer M; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
Nat Commun; 2023 Apr; 14(1):2147. PubMed ID: 37072421
[TBL] [Abstract][Full Text] [Related]
3. Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Österborg A; Hansson L
Br J Haematol; 2020 Nov; 191(3):426-432. PubMed ID: 32779190
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.
Wang Y; Zhou S; Qi X; Yang F; Maurer MJ; Habermann TM; Witzig TE; Wang ML; Nowakowski GS
Blood Cancer J; 2022 Jan; 12(1):1. PubMed ID: 34987165
[TBL] [Abstract][Full Text] [Related]
5. Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia.
Johnson PC; Woyach JA; Ulrich A; Marcotte V; Nipp RD; Lage DE; Nelson AM; Newcomb RA; Rice J; Lavoie MW; Ritchie CS; Bartlett N; Stephens DM; Ding W; Owen C; Stone R; Ruppert AS; Mandrekar SJ; Byrd JC; El-Jawahri A; Le-Rademacher J; Rosko A
J Geriatr Oncol; 2023 Jul; 14(6):101538. PubMed ID: 37329769
[TBL] [Abstract][Full Text] [Related]
6. Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Sharman JP; Miranda P; Roos J; Emeribe U; Cai L; Liljas B; Gaitonde P
Leuk Lymphoma; 2023; 64(7):1243-1252. PubMed ID: 37221877
[TBL] [Abstract][Full Text] [Related]
7. HPLC-UV and GC-MS Methods for Determination of Chlorambucil and Valproic Acid in Plasma for Further Exploring a New Combined Therapy of Chronic Lymphocytic Leukemia.
Lipska K; Gumieniczek A; Pietraś R; Filip AA
Molecules; 2021 May; 26(10):. PubMed ID: 34068372
[TBL] [Abstract][Full Text] [Related]
8. Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis.
Kongnakorn T; Sterchele JA; Salvador CG; Getsios D; Mwamburi M
Clinicoecon Outcomes Res; 2014; 6():141-9. PubMed ID: 24729719
[TBL] [Abstract][Full Text] [Related]
9. Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center.
Arguello-Tomas M; Albiol N; Jara P; Garcia-Cadenas I; Redondo S; Esquirol A; Novelli S; Saavedra S; Martino R; Nomdedeu J; Sierra J; Mora A; Moreno C
Leuk Lymphoma; 2023 Oct; 64(10):1655-1661. PubMed ID: 37452739
[TBL] [Abstract][Full Text] [Related]
10. Are small lymphocytic lymphoma and chronic lymphocytic leukemia the same disease? The unsolved dilemma.
Cencini E; Calomino N; Sicuranza A; Gozzetti A; Fabbri A; Bocchia M
J Chemother; 2023 Dec; ():1-5. PubMed ID: 38079237
[TBL] [Abstract][Full Text] [Related]
11. Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).
Kutsch N; Bahlo J; Robrecht S; Franklin J; Zhang C; Maurer C; De Silva N; Lange E; Weide R; Kiehl MG; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Herling M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Böttcher S; Stilgenbauer S; Fink AM; Hallek M; Eichhorst B
Hemasphere; 2020 Feb; 4(1):e336. PubMed ID: 32072150
[TBL] [Abstract][Full Text] [Related]
12. Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.
Molica S; Shanafelt TD; Allsup D; Giannarelli D
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539420
[TBL] [Abstract][Full Text] [Related]
13.
Zhang Z; Chen S; Chen S; Chen G; Zhang R; Li J; Qu J
Oncotarget; 2017 Sep; 8(41):69916-69923. PubMed ID: 29050251
[TBL] [Abstract][Full Text] [Related]
14. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
Sportoletti P; Laurenti L; Chiarenza A; Gaidano G; Albi E; Mauro FR; Trentin L; Vallisa D; Pane F; Cuneo A; Albano F; Zamprogna G; Coscia M; Gozzetti A; Reda G; Caira M; Finsinger P; Gualberti G; Iannella E; Malgieri S; Molica S
Hematol Oncol; 2024 Jan; 42(1):e3216. PubMed ID: 37772620
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL).
Ma H; O'Brien S; Gupta P
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):77-82. PubMed ID: 37743181
[TBL] [Abstract][Full Text] [Related]
16. Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.
Owen C; Gerrie AS; Banerji V; Assouline S; Chen C; Robinson KS; Lye E; Fraser G
Curr Oncol; 2018 Oct; 25(5):e461-e474. PubMed ID: 30464698
[TBL] [Abstract][Full Text] [Related]
17. The effect of mind-body intervention on lymphocyte doubling time and treatment free survival in treatment-naïve chronic lymphocytic leukemia patients.
Shapira S; Hirschberger N; Ofran Y; Mizrahi B; Mandel E; Benjamini O; Rabinowicz N; Zoref-Lorenz A
Acta Haematol; 2024 Mar; ():. PubMed ID: 38461815
[TBL] [Abstract][Full Text] [Related]
18. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Al-Sawaf O; Zhang C; Jin HY; Robrecht S; Choi Y; Balasubramanian S; Kotak A; Chang YM; Fink AM; Tausch E; Schneider C; Ritgen M; Kreuzer KA; Chyla B; Paulson JN; Pallasch CP; Frenzel LP; Peifer M; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
Nat Commun; 2023 Oct; 14(1):6724. PubMed ID: 37872229
[No Abstract] [Full Text] [Related]
19. Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units.
Salvi G; Innocenti I; Autore F; Laurenti L
Mediterr J Hematol Infect Dis; 2015; 7(1):e2015056. PubMed ID: 26543525
[TBL] [Abstract][Full Text] [Related]
20. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
Voorhies BN; Stephens DM
Curr Treat Options Oncol; 2017 Feb; 18(2):12. PubMed ID: 28243993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
